Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease - PubMed (original) (raw)
Review
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Amedeo Lonardo et al. Expert Rev Gastroenterol Hepatol. 2015 May.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as an important cardiovascular risk (CVR) factor. This is a narrative clinical review aimed at answering how diagnosis and management of CVR should be conducted in the individual patient with NAFLD. To this end, the authors performed an extensive search of the existing literature on PubMed (1993-2014) using pertinent keywords. To date, CVR among patients with NAFLD might be assessed with the Framingham risk score equation or other risk calculators, to be adapted to the true CVR in the specific population being assessed; however, the use of these CVR calculators needs to be validated by future studies in larger cohorts of NAFLD patients of various ethnic backgrounds in order to substantiate their clinical relevance as a foundation for the primary prevention of cardiovascular diseases in this group of patients. Early and aggressive drug treatment of CVR should be started in NAFLD patients with a history of cardiovascular events, established diabetes or who are at high (calculated) CVR. Whether such an aggressive pharmacological approach is also justified in patients with NAFLD, who are at intermediate or low CVR, remains debatable. Currently, there are no clinical trials showing that the treatment of NAFLD per se (either associated or unassociated with traditional CVR factors) will result in decreased risk of cardiovascular events. Accordingly, drug treatment should be better individualized, aiming at correcting all the coexisting cardio-metabolic risk factors of the individual patient with NAFLD. To this end, an overview of the lifestyle interventions and the available drugs is offered, emphasis being conveyed to statins and metformin, which promise to cover worrying complications of NAFLD such as the risk of developing hepatocellular carcinoma.
Keywords: Framingham risk score; HCC; NASH; cardiovascular risk; metformin; statins; steatosis.
Similar articles
- Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, Ratziu V, Lonardo A. Loria P, et al. Atherosclerosis. 2014 Jan;232(1):99-109. doi: 10.1016/j.atherosclerosis.2013.10.030. Epub 2013 Nov 6. Atherosclerosis. 2014. PMID: 24401223 Review. - NAFLD: a multisystem disease.
Byrne CD, Targher G. Byrne CD, et al. J Hepatol. 2015 Apr;62(1 Suppl):S47-64. doi: 10.1016/j.jhep.2014.12.012. J Hepatol. 2015. PMID: 25920090 Review. - Nonalcoholic fatty liver disease and statins.
Tziomalos K, Athyros VG, Paschos P, Karagiannis A. Tziomalos K, et al. Metabolism. 2015 Oct;64(10):1215-23. doi: 10.1016/j.metabol.2015.07.003. Epub 2015 Jul 8. Metabolism. 2015. PMID: 26234727 Review. - Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS, Longo L, Fonseca MA, de Souza VEG, Álvares-da-Silva MR. Guerreiro GTS, et al. Hepatol Int. 2021 Apr;15(2):380-391. doi: 10.1007/s12072-021-10157-y. Epub 2021 Mar 10. Hepatol Int. 2021. PMID: 33694066 - Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
Luo J, Xu L, Li J, Zhao S. Luo J, et al. Eur J Gastroenterol Hepatol. 2015 Mar;27(3):193-9. doi: 10.1097/MEG.0000000000000254. Eur J Gastroenterol Hepatol. 2015. PMID: 25563143 Review.
Cited by
- Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo A, Ballestri S, Mantovani A, Targher G, Bril F. Lonardo A, et al. Metabolites. 2024 Jan 8;14(1):40. doi: 10.3390/metabo14010040. Metabolites. 2024. PMID: 38248843 Free PMC article. Review. - Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease.
Kotlyarov S, Bulgakov A. Kotlyarov S, et al. Cells. 2021 Nov 1;10(11):2978. doi: 10.3390/cells10112978. Cells. 2021. PMID: 34831201 Free PMC article. Review. - The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments.
Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. Siphepho PY, et al. Biomedicines. 2021 Oct 17;9(10):1491. doi: 10.3390/biomedicines9101491. Biomedicines. 2021. PMID: 34680608 Free PMC article. Review. - Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P. Nahra R, et al. Diabetes Care. 2021 Jun;44(6):1433-1442. doi: 10.2337/dc20-2151. Epub 2021 May 20. Diabetes Care. 2021. PMID: 34016612 Free PMC article. Clinical Trial. - Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.
Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Ballestri S, et al. Diagnostics (Basel). 2021 Jan 9;11(1):98. doi: 10.3390/diagnostics11010098. Diagnostics (Basel). 2021. PMID: 33435415 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical